HDAC9 and Alzheimer disease: Although the first therapeutic strategies using HDAC inhibitors have been successful in AD-like mouse models (Francis et al., 2009) its translation into a clinical trial for NDDs seems to be much more challenging, as HDAC inhibitors may also have neurotoxic side effects (see review Shukla and Tekwani, 2020).